SCHEMBL2927973

SCHEMBL2927973

CCCC(=O)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.63
NR5A2 O00482 1/20 0.61
NR5A1 Q13285 1/20 0.61
MAPT P10636 1/20 0.59
PLA2G1B P04054 1/20 0.50
PLA2G2A P14555 1/20 0.50
RECQL P46063 1/20 0.49
ADRA1D P25100 1/20 0.49
PTAFR P25105 1/20 0.49
HTR1D P28221 1/20 0.49
HTR2C P28335 1/20 0.49
ADRA1B P35368 1/20 0.49
DRD3 P35462 1/20 0.49
TMEM97 Q5BJF2 1/20 0.49
LMNA P02545 2/20 0.49
AKT1 P31749 2/20 0.49
ESR1 P03372 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
CDC25A P30304 1/20 0.49
AGTR1 P30556 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20067445 1.00 SMN1; SMN2 (0.63) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL23352264 0.91 SMN1; SMN2 (0.74) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL29540787 0.91 SMN1; SMN2 (0.74) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
Lysophosphatidylcholine SCHEMBL19787878 0.90 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL11131776 0.90 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL31577414 0.90 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL9560238 0.90 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL25336885 0.90 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL19065066 0.90 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B
SCHEMBL9015289 0.90 SMN1; SMN2 (0.76) SMN1; SMN2NR5A2NR5A1MAPTPLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 EP disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
EP-2230312-A1 Probe compound for detecting and isolating enzymes and means and methods using the same Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2010-09-22 EP disclosed